155 related articles for article (PubMed ID: 35313079)
1. CRISPR-mediated knockout of VEGFR2/KDR inhibits cell growth in a squamous thyroid cancer cell line.
Tsai ML; Lee CH; Huang LC; Chen YH; Liu WN; Lin CY; Hsu KW; Lee AW; Lin CL
FEBS Open Bio; 2022 May; 12(5):993-1005. PubMed ID: 35313079
[TBL] [Abstract][Full Text] [Related]
2. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.
Kim DS; Franklyn JA; Boelaert K; Eggo MC; Watkinson JC; McCabe CJ
J Clin Endocrinol Metab; 2006 Nov; 91(11):4603-11. PubMed ID: 16926250
[TBL] [Abstract][Full Text] [Related]
3. HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer.
Lin CL; Tsai ML; Lin CY; Hsu KW; Hsieh WS; Chi WM; Huang LC; Lee CH
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669676
[TBL] [Abstract][Full Text] [Related]
4. Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.
Kim JY; Hwang J; Lee SH; Lee HJ; Jelinek J; Jeong H; Lim JS; Kim JM; Song KS; Kim BH; Lee S; Kim J
Clin Epigenetics; 2015; 7():99. PubMed ID: 26380584
[TBL] [Abstract][Full Text] [Related]
5. Platelet-Derived Growth Factor Receptor-α Subunit Targeting Suppresses Metastasis in Advanced Thyroid Cancer
Lin CL; Tsai ML; Chen YH; Liu WN; Lin CY; Hsu KW; Huang CY; Chang YJ; Wei PL; Chen SH; Huang LC; Lee CH
Biomol Ther (Seoul); 2021 Sep; 29(5):551-561. PubMed ID: 34031270
[TBL] [Abstract][Full Text] [Related]
6. Novel hKDR mouse model depicts the antiangiogenesis and apoptosis-promoting effects of neutralizing antibodies targeting vascular endothelial growth factor receptor 2.
Cao Y; Sun C; Huo G; Wang H; Wu Y; Wang F; Liu S; Zhai S; Zhang X; Zhao H; Hu M; Gu W; Yang Y; Wang S; Liang C; Lyu J; Lu T; Wang Y; Xie L; Fan C
Cancer Sci; 2023 Jan; 114(1):115-128. PubMed ID: 36114822
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J
Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
[TBL] [Abstract][Full Text] [Related]
9. The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.
Zietsch J; Ziegenhagen N; Heppner FL; Reuss D; von Deimling A; Holtkamp N
PLoS One; 2010 Jul; 5(7):e11858. PubMed ID: 20686603
[TBL] [Abstract][Full Text] [Related]
10. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
Seto T; Higashiyama M; Funai H; Imamura F; Uematsu K; Seki N; Eguchi K; Yamanaka T; Ichinose Y
Lung Cancer; 2006 Jul; 53(1):91-6. PubMed ID: 16697074
[TBL] [Abstract][Full Text] [Related]
12. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer.
Huang LC; Tam KW; Liu WN; Lin CY; Hsu KW; Hsieh WS; Chi WM; Lee AW; Yang JM; Lin CL; Lee CH
Dis Markers; 2018; 2018():3835783. PubMed ID: 29849821
[TBL] [Abstract][Full Text] [Related]
14. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
[TBL] [Abstract][Full Text] [Related]
15. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
[TBL] [Abstract][Full Text] [Related]
16. The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation.
Kim JY; Hwang JH; Zhou W; Shin J; Noh SM; Song IS; Kim JY; Lee SH; Kim J
Epigenetics; 2009 Jul; 4(5):313-21. PubMed ID: 19633424
[TBL] [Abstract][Full Text] [Related]
17. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer.
Rydén L; Linderholm B; Nielsen NH; Emdin S; Jönsson PE; Landberg G
Breast Cancer Res Treat; 2003 Dec; 82(3):147-54. PubMed ID: 14703061
[TBL] [Abstract][Full Text] [Related]
18. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
19. Interactions of Vascular Endothelial Growth Factor and p53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic Targets in Aggressive Thyroid Cancers.
Maroof H; Irani S; Arianna A; Vider J; Gopalan V; Lam AK
Curr Cancer Drug Targets; 2019; 19(7):561-570. PubMed ID: 29956628
[TBL] [Abstract][Full Text] [Related]
20. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay.
Knizetova P; Ehrmann J; Hlobilkova A; Vancova I; Kalita O; Kolar Z; Bartek J
Cell Cycle; 2008 Aug; 7(16):2553-61. PubMed ID: 18719373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
